首页> 外文期刊>Journal of drugs in dermatology: JDD >Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males
【24h】

Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males

机译:Tazarotene 0.045%乳液曾经每日治疗成年男性中度至严重的痤疮紫色

获取原文
获取原文并翻译 | 示例
       

摘要

Background: There has been an increasing interest in gender differences both in the pathogenesis and treatment of acne vulgaris (acne). However, while acne prevalence among adolescents is comparable across sexes, acne is much more common in adult women than in adult men which has been largely ignored. Acne is likely less common in adult men because of the declining rate of sebum secretion observed with increasing age, and yet it can be more severe than in adult women. In addition, adherence to topical medications is especially poor in adult men where tactile and sensory perceptions are low. The first lotion formulation of tazarotene was developed using polymeric emulsion technology to provide an important alternative option to treat these acne patients, especially those who may be sensitive to the irritant effects of other tazarotene formulations.
机译:背景:在祛痰(痤疮)的发病机制和治疗中,对性别差异的兴趣越来越令人兴趣。 然而,虽然青少年之间的粉刺患病率在性别上具有相当的比较,但痤疮在成年女性中比在基本上被忽视的成年男性更常见。 由于随着年龄增加观察到的皮脂分泌率下降,痤疮可能不太常见,但随着年龄的增加,它可能比成年女性更严重。 此外,在触觉和感官感知低的成年男性中遵守局部药物的粘附尤其差。 使用聚合物乳液技术开发了塔拉替烯的第一种乳液制剂,以提供一种重要的替代选择来治疗这些痤疮患者,尤其是那些对其他达拉管配方的刺激作用敏感的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号